<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870961</url>
  </required_header>
  <id_info>
    <org_study_id>NU 08I3</org_study_id>
    <secondary_id>P30CA060553</secondary_id>
    <secondary_id>NU-08I3</secondary_id>
    <secondary_id>STU00005964</secondary_id>
    <nct_id>NCT00870961</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps</brief_title>
  <official_title>Vitamin D Intervention For Colon Cancer Prevention In African-Americans-A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use&#xD;
      of vitamin D may keep colorectal cancer from forming in patients with colon polyps.&#xD;
&#xD;
      PURPOSE: This randomized phase I trial is studying a vitamin D supplement to see how well it&#xD;
      works compared with a placebo in preventing colorectal cancer in African Americans with colon&#xD;
      polyps.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the accrual rate of African Americans with adenomatous polyps to a 6-month&#xD;
           randomized intervention trial comprising supplementation with either cholecalciferol&#xD;
           (vitamin D3) or placebo.&#xD;
&#xD;
        -  To determine the compliance rates in patients treated with these regimens.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To compare changes in pre- and post-treatment vitamin D levels in patients treated with&#xD;
           these regimens.&#xD;
&#xD;
        -  To correlate vitamin D levels with vitamin D modifiers, such as levels of skin&#xD;
           pigmentation, dietary vitamin D intake, and sun exposure in this patient population.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral cholecalciferol (vitamin D3) supplementation daily for up&#xD;
           to 6 months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo supplementation daily for up to 6 months in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients complete questionnaires about demographics, dietary vitamin D intake, personal&#xD;
      history (e.g., ancestry, alcohol and tobacco intake, occupation, height, and weight), medical&#xD;
      history (e.g., personal and family history of colorectal cancer and polyps), and ultraviolet&#xD;
      radiation exposure.&#xD;
&#xD;
      Blood samples are collected at baseline and at 6 months for correlative laboratory studies.&#xD;
      Blood samples are analyzed for vitamin D levels by enzyme immunoassay. Patients also undergo&#xD;
      assessment of skin pigmentation in sunprotected and sunexposed areas of skin by reflectance&#xD;
      spectrometry at baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI changed institutions and accrual was not completed.&#xD;
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of compliance as assessed at 6 months</measure>
    <time_frame>Following 6 months of study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of accrual</measure>
    <time_frame>After accrual goal is reached</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in pre- and post-treatment vitamin D levels</measure>
    <time_frame>At baseline and following completion of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of vitamin D levels with vitamin D modifiers (e.g., levels of skin pigmentation, dietary vitamin D intake, and sun exposure)</measure>
    <time_frame>After completion of study treatment &amp; final colonic biopsy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral cholecalciferol (vitamin D3) supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenomatous polyp&#xD;
&#xD;
               -  At least 1 adenoma&#xD;
&#xD;
          -  Self-identified as an African American AND undergoing screening or diagnostic&#xD;
             colonoscopy at the University of Chicago&#xD;
&#xD;
          -  No history of colon or rectal cancer or hereditary or familial colon cancer (e.g.,&#xD;
             hereditary non-polyposis colon cancer or familial adenomatous polyposis)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Total bilirubin normal&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Albumin ≥ 3.0 mg/dL&#xD;
&#xD;
          -  Baseline serum calcium level normal&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No history of thyroid disease&#xD;
&#xD;
          -  No history of renal stones&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other concurrent vitamin D intake&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Halla Nimeiri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2009</study_first_posted>
  <last_update_submitted>September 13, 2013</last_update_submitted>
  <last_update_submitted_qc>September 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <keyword>rectal cancer</keyword>
  <keyword>adenomatous polyp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

